

1 High seroprevalence after the second wave of SARS-COV2 respiratory infection in a small
2 settlement on the northern coastal of Peru.

3

4 Angie K. Toledo^{1,2}, Franco León-Jimenez^{3,4}, Sofia Cavalcanti⁴, Percy Vilchez-Barreto⁵, Narcisa
5 Reto⁶, Jessica Vega⁷, Lucia M Bolivar⁸, Matilde Rhor⁹, Jhon Ypanaque⁹, Henry Silva^{9,10}, and Luz
6 M. Moyano^{3*}, Group of Neuroepidemiology and Science of Life of Peru.

7

8 1. School of Public Health and Administration, Universidad Peruana Cayetano Heredia, Lima,
9 Peru

10 2. Centro de investigación para la preservación de la vida, Lima, Peru

11 3. Escuela de Medicina Humana, Universidad Cesar vallejo

12 4. Dirección de Investigación Hospital Amistad Perú-Korea Sta. Rosa II-2, Piura Peru

13 5. Centro de Salud Global, Universidad Peruana Cayetano Heredia, Tumbes, Peru

14 6. Hospital I Carlos Alberto Cortés Jiménez Essalud, Tumbes, Peru

15 7. Dirección ejecutiva de epidemiología (Chief), Centro de Salud Pampa Grande, Regional
16 Directorate of Health, Tumbes, Peru

17 8. Centro de Salud Pampa Grande, Regional Directorate of Health, Tumbes, Peru.

18 9. Psychology School (MR), Social and Cultural Office (JY), and Economy and Political Science
19 School (HS), Universidad Nacional de Tumbes, Tumbes, Peru

20 10. Unidad Médico legal II Tumbes, Instituto de Medicina Legal del Peru.

21

22 * Immoyanom@ucvvirtual.edu.pe (LMM)

23 Short title: Tumbes, Peru: High Covid-19 seroprevalence during second wave

24

25

26

27

28 **Abstract**

29 **Background.** Due to more infections from variations that could escape vaccination and immunity
30 by asymptomatic to uninfected transmission, COVID-19's second wave had higher seroprevalence
31 globally. Public health constraints and herd immunity may not work against these novel variations'
32 infectivity. This population-based study in Peru's Tumbes Region during the second wave of
33 COVID-19 seeks to determine seroprevalence and demographic changes from the first wave.

34 **Methodology/Principal findings.** In Dec 2021-Jan 2022, a study in Tumbes' informal settlement
35 sampled individuals over 2 years old from one in every four households. Finger-prick blood
36 samples and symptom surveys were collected. On the second wave, there was a substantial rise in
37 adjusted seroprevalence (50.15%, 95% CI [45.92 – 54.40]) compared with the first wave (24.82 %,
38 95%CI [22.49 – 27.25]), with females maintaining a higher seroprevalence (53.89; 95% CI [48.48-
39 59.23]) vs. 45.49; 95% CI [38.98-52.12], $p=0.042$) compare to males. Those under 18 years of age
40 had the highest IgG seropositivity: the 12–17 age group during the second wave (85.14%) and the
41 2–11 age group (25.25%) during the first wave. Nasal congestion and cough were symptoms
42 associated with seropositivity, unlike the first wave.

43 **Conclusions/Significance.** In Tumbes, the seroprevalence of COVID-19 increased by twofold
44 compared to the initial wave. Inadequate infrastructure and limitations in human resources and
45 supplies in healthcare facilities made the Peruvian health system collapse. We must include in
46 epidemiological surveillance mHealth tools that enable real-time reporting of new cases. Working
47 alongside the community is the only way to improve any new intervention strategy to prevent or
48 control a new pandemic.

49 **Author summary**

50 In Peru, the healthcare system was overwhelmed by the COVID-19 pandemic due to the lack of
51 hospital capacity, oxygen supply, political unrest, and a fragmented healthcare system. During the
52 first wave, the prevalence ranged from 20.8% to 72%, and it was predicted that the second wave
53 would be disastrous. To assess the seroprevalence of SARS-CoV-2, a cross-sectional study was
54 conducted in the settlement "AAHH Las Flores" located in front of Tumbes National University's
55 main campus. A door-to-door intervention was conducted, and a total of 580/781 (74.26%)
56 individuals over than 2 years and above agreed to participate. After adjusting for sensitivity and
57 specificity, the calculated adjusted seroprevalence was 50.15%. Women had a slightly higher
58 adjusted seroprevalence compared to men, and the age groups with the highest prevalence of IgG
59 seropositive were from 12 to 17 years, from 30 to 59 years, and older than 60 years. More than 80%
60 of seropositive patients were asymptomatic in all age groups. The study's findings suggest that
61 COVID-19 transmission in the settlement was higher during the second wave, and asymptomatic
62 individuals could have played a critical role in spreading the virus.

63 **Introduction**

64 Due to a lack of hospital capacity, critical oxygen supply, political unrest, and a fragmented
65 healthcare system, Peru experienced high rates of morbidity and mortality during the first and
66 second catastrophic waves (1–3). Prevalence rates on the first wave ranged from 20.8% to 72%
67 (1,2,4,5). Without the option of massive vaccination, a disastrous second wave was expected unless
68 the health system responded adequately. On December 17th, 2021, in the Tumbes district, close to
69 93% of the population over 18 years old and seniors had received the first dose of the Sinopharm
70 and Pfizer COVID-19 vaccine. 75% of the population between the ages of 12 and 17 was
71 vaccinated, while no one under the age of 12 had been immunized (6). The first wave hit Peru in
72 March 2020, peaked in August, and declined in December 2020 (7). The second wave started in
73 January, with the highest number of infections and deaths decreasing in June 2021. Throughout a
74 significant portion of the second wave, the number of daily infections consistently exceeded the
75 number of daily recoveries. The peak was observed during week 54, specifically from March 22nd
76 to 28th, with an average of 9,079 new infections and 8,727 recoveries per day (8,9). The highest
77 attack rate (6.96) was for 30- to 59-year-olds, followed by 6.56 for adults aged 60 and above. (9).
78 During this same period, Tumbes had the seventh highest cumulative attack rate (5.29), compared
79 with the national average of 4.84. The Tumbes case fatality rate rose from 3.54% to 9.40% on
80 May's last day of 2021. Peru was fifth in the world for deaths per 100,000 people (10), behind the
81 United States, Brazil, India, and Mexico (2,9). In April 2021, during the peak of cases, the Tumbes
82 region had three hospitals, 17 beds in the ICU, and 20 mechanical ventilators(11).

83

84 A cross-sectional study conducted in a rural village of Tumbes (Puerto Pizarro) during the final
85 days of the first wave found an adjusted seroprevalence of 24.82% (12) where; with being a woman
86 [28.03%, $p=0.002$], water storage [PR 1.37, $p=0.034$], and symptoms such as fever, general
87 discomfort, cough, nasal congestion, respiratory distress, headache, anosmia, and ageusia being

88 variables associated with a positive antibody rapid-test of Sars-cov-2 (12,13). Taking full advantage
89 of the regional program of active surveillance of the Tumbes Government (GORE) and Regional
90 Directorate of Health (DIRESA) (14), we conducted a cross-sectional study in a human settlement
91 named AAHH Las Flores (n = 781 population): a) to assess seroprevalence of SARS-CoV-2 at the
92 end of the second wave, b) to determine distribution by age group, and health determinants
93 associated with residents over 2 years old.

94

95 **Materials and methods**

96 **Ethical considerations**

97 Approval for the study protocol and consent forms was obtained from the institutional review
98 boards of Universidad Peruana Cayetano Heredia and the Regional Directorate of Health (DIRESA,
99 Spanish acronym) in Tumbes. To ensure comprehension, illiterate individuals were included by
100 having the IC and survey read aloud to them. All participants provided written informed consent
101 (IC) in the presence of a witness (S1 Text). For minors, both the minor and their parents or legal
102 guardians provided written informed consent (S2 Text).

103

104 **Area and study population**

105 The settlement "AAHH Las Flores," which has a population of 781 individuals, is located in the
106 Pampa Grande Population Center in the district and province of Tumbes. It is situated 2.5km away
107 from the town center and lacks proper infrastructure, with unpaved streets and no continuous access
108 to safe drinking water (15). The population is of a homogeneous mestizo ethnicity. According to the
109 last national census, the population of this settlement was 721 individuals, with a total of 184
110 households. Also, 94.5%, had access to potable water and 95.1% had access to sewage disposal
111 (16).

112 The Pampa Grande health facility was staffed by six physicians, six nurses, six midwives, one
113 pediatrician, and six nursing technicians. It provides 24/7 service and has an ambulance for
114 emergency transportation (17).

115

116 **Study design and sampling**

117 A cross-sectional analytical approach was used to invite and enroll individuals over than 2 years
118 and above (n=781 pop) through a door-to-door intervention conducted between December 2021 and
119 the first day of January 2022. This intervention took place after the second wave and a few weeks
120 before the start of the third wave.

121

122 The recruitment process, censuses, and rapid antibody testing for COVID-19, were described
123 elsewhere (12,13). Briefly, the regional directorate of Health-Tumbes and the Center for Global
124 Health collaborated to conduct a nominal census with block-numbered homes. Individuals over the
125 age of two who stayed in the village at least three nights per week and consented to sign the
126 informed consent form were eligible to participate. The study included 781 individuals who met
127 these criteria. Non-medical field workers collected blood samples via finger prick and explained the
128 results of the lateral flow test to everyone surveyed. Clinical signs suggestive of COVID-19 disease
129 were evaluated in accordance with WHO criteria (18). Trained physicians from the study team
130 evaluated participants with respiratory symptoms, and data was entered into the Notiweb and
131 SISCOVID databases for follow-up by the healthcare system. The COVID-19 Clinical
132 Epidemiological Investigation format was used to identify symptoms experienced within the
133 previous 14 days, as recommended by the Peruvian Ministry of Health (19).

134

135 A census previously validated by the Center for Global Health in epidemiological population-based
136 investigations was used in this study (20,21). Comorbidities were determined as the existence of at

137 least one of the following medical disorders: hypertension, diabetes, hepatic disease, renal disease,
138 lung disease, asthma, obesity, neurological problems, HIV, cancer, or tuberculosis (22).

139

140 **Definitions and operationalization of variables**

141 The seroprevalence of SARS-CoV-2 was determined by dividing the number of participants who
142 tested positive for IgG, IgM, or both in a lateral flow test by the total number of participants. The
143 variables: sex, "type of family", rooms per person , water supply and water storage were describe in
144 a previously research (12). "Latrines/don't have" and "other and restrooms," which are designated as
145 places with a toilet, sink, network connection, and drainage, are the two categories for the variable
146 for hygienic services (12). Visual examination was used to confirm the factors related to the water
147 supply, water storage, and hygiene services. A lateral flow test was declared positive when IgG,
148 IgM, or both findings were observed.

149

150 **Statistical analysis**

151 The SARS-CoV-2 seroprevalence ratios in Las Flores settlement were aimed to be estimated by
152 performing descriptive statistics and binomial family generalized linear models with a logarithmic
153 link function, while controlling for other variables, such as age, sex, type of family, water storage,
154 and basic hygienic services at home. Household clustering was accounted for by using robust
155 sandwich-type standard errors. Each variable was evaluated for inclusion in the final model using
156 the log likelihood ratio. 95% confidence intervals (CIs) were reported, and statistical significance
157 was set at $P < 0.05$. The seroprevalence was adjusted for the test's reported sensitivity (99.03%) and
158 specificity (98.65%). The statistical analysis was performed using Stata v 17.0 software (College
159 Station, Texas 77845, USA).

160

161 **Results**

162 A total of 580/781 (74.26%) individuals older than 2 years old agreed to participate. Female
163 participants were 59.83 % (347/580). The overall participants' mean age was 28.80 ± 19.36 years.
164 MINSA stratification mean ages were from: 2 to 11 years (mean 6.83 ± 2.81), 12 to 17 years (mean
165 14.53 ± 1.81), 18 to 29 years (mean 23.60 ± 3.23), 30 to 59 years (mean 44.00 ± 7.98) and older than 60
166 years (mean 67.84 ± 6.80). Most people lived in single families 391/580 (67.41 %), had access to
167 public potable water 342/580 (58.97%) for 02-04 hours per day and 454/580 (78.28 %) had access
168 to hygienic services.

169

170 **Seroprevalence**

171 Anti-SARS-CoV-2 antibodies were detected in 292/580 (50.34 %) participants: 282 IgG reactive, 8
172 IgM/IgG reactive, and 2 IgM reactive. After adjusting for sensitivity (99.03%) and specificity
173 (98.65%), the calculated adjusted seroprevalence was 50.15 % (95% CI: 45.92 - 54.40). Women
174 had a slightly higher adjusted seroprevalence compared to men (53.89 [95% CI: 48.48 - 59.23] vs.
175 45.49 [95% CI: 38.98 - 52.12], $p=0.042$). No other demographic characteristics were associated
176 with SARS-CoV-2 lateral flow test seropositivity (Table 1).

177

178 **Table 1. Seroprevalence adjusted for participant characteristics and associated factors from**
179 **first and second COVID-19 wave.**

180

181 As illustrated in Fig 1, the age groups with the highest prevalence of IgG seropositive were from 12
182 to 17 years (85.14%), from 30 to 59 years (59.80 %) and older than 60 years (55.81%). On the other
183 hand, more than 80% of seropositive patients were asymptomatic in all age groups (Figure 2).

184

185 **Fig 1. Seronegative and seropositivity from first and second COVID-19 wave.**

186

187 **Fig 2. Symptomatic and asymptomatic cases in the seropositive population from first and**
188 **second COVID-19 wave.**

189

190 In a bivariate analysis, symptoms such as cough (PR: 1.74; 95% CI: [1.27 - 2.38], p=0.001) and
191 nasal congestion (PR: 0.60, 95% CI: [0.36 - 0.99], p=0.045) were associated with SARS-CoV-2
192 seropositivity. Both symptoms were associated with seropositivity in a multiple analysis (PR: 4.15,
193 95% CI: [1.90 - 9.07], p<0.001) and (PR: 0.41; 95% CI: [0.20 - 0.84], p=0.014) (Table 2).

194

195 **Table 2. Self-reported symptoms seropositive and seronegative participants from first and second**
196 **COVID-19 wave.**

197

198 **Discussion**

199 In the second wave, a higher COVID-19 prevalence was reported globally compared to the first
200 wave. In Peru, it grew by 100 percent between November 2020 (first wave) and December 2021
201 (second wave). This research group conducted two population-based studies in the Tumbes Region,
202 revealing the same trend (24.82% vs. 50.15%) (S1 Fig), contradictory to Regional directorate of
203 health Tumbes reported (6.11%) (14). This numbers were similar to reported in Italy, which had a
204 seroprevalence of over 50% in the second wave (23), and higher than Japan, which doubled its
205 caseload (24). Seroprevalence increased as more people were infected with the virus and its
206 different variants that could escape vaccination (25) and the immunity generated by contagion from
207 the asymptomatic to the uninfected (26). In addition, these variants resulted in variations in
208 transmissibility, disease severity, risk of reinfection, diagnostic failures, natural immunity,
209 vaccination efficacy, and treatment. Persistent community transmission in regions with a higher

210 vaccination rate or history of infection may indicate the presence of a variant capable of evading the
211 immune response (27). The new variants began to appear in the world at the end of 2020, right at
212 the end of the first study, as variants of interest (VOI) and variants of concern (VOC) according to
213 the WHO; the Delta variant began to circulate in October 2021 and could be the variant that
214 explains this high seroprevalence (28). According to a weekly report from the INS, in Peru, at the
215 end of August 2021, the delta variant corresponded to 40% of the samples, gamma was 37%,
216 lambda was 17%, and the mu variant was 5% (29). In Tumbes, in the 20–30-year-old group. From
217 January to November 2022, omicron (n = 463) and delta (n = 125) variants were identified (30).

218

219 The delta variant generated a lower response to mRNA vaccines (Pfizer-BioNTech and Moderna
220 NIH), viral vectors (Oxford-AstraZeneca) (31), as well as inactivated viruses (Sinopharm-Beijing)
221 (32). On December 19, 2022, the coverage with three doses of vaccines in Tumbes was as follows:
222 55.1% for adolescents, 77.15 % for young persons, 77.9 % for adults, and 82.5 % for the elderly.
223 Indicative of adequate coverage, the majority of doses were distributed by Pfizer (56%),
224 AstraZeneca (19.7%), Sinopharm (17%), and Moderna (7.2%) (33). In addition, the WHO classified
225 the omicron variant as concerning on November 26, 2021. Although the classic public health
226 restriction measures may be effective against the new variants, they are less effective in terms of
227 infectivity; on the other hand, herd immunity achieved with a previous variant might not be helpful
228 (28).

229

230 Seroprevalence in the second wave (53.89 [48.48-59.23]) was higher compared to other Reports of
231 the second wave in Peru, where there were no gender differences (2,14), similar in France (Corsica)
232 (34); our numbers were lower compared to the Democratic Republic of the Congo (74.3% vs.
233 68.3%; p = 0.021) (35), Kashmir, India (86.21 [85.86-86.55])(36) and slightly higher compared to
234 Delhi, India (52.42,OR 1.16[1.10-1.23],p<0.001)(37). A possible explanation for this increased
235 seroprevalence in women is that they were the ones caring for positive cases at home (38); there are

236 more female health workers than male health workers (nurses, nurse technicians, and midwives)
237 (39); women purchase supplies in stores and markets, and this overexposure could lead to an
238 increase in COVID-19 infection.

239

240 There were many possible explanations for the only statistically significant clinical manifestations
241 in this second wave (cough and nasal congestion): the new variants sacrificed their virulence for
242 their infectious capacity, so we observed in the delta variant there was some variability in clinical
243 expression compared to the original virus strain (40); people gained more knowledge about
244 COVID-19 on the second wave, may have contributed to the increased prevalence of clinical
245 manifestations.

246

247 One of the limitations of this research is the sample size and the fact that the study was conducted in
248 a single settlement, limiting the generalizability of the findings to other regions of Peru. The limited
249 availability of rapid tests, which have lower sensitivity and specificity compared to PCR tests; and
250 finally, the study did not collect data on participants' vaccination status; this information was
251 obtained from reports of the Ministry of Health. With persistent IgG seropositivity, it is
252 recommended that follow-up be conducted to detect COVID-19 sequelae related to the
253 presence of pulmonary lesions, mental health issues and, the implementation of an application-
254 based surveillance system in our country. Many systematic reviews and meta-analyses revealed
255 that 62.2% of asymptomatic patients had tomographic abnormalities, indicating that they are a
256 potential source of transmission (41)

257 Our research has several implications for Peru's public health policy. First, the high seroprevalence
258 indicates that a substantial portion of the population may already be infected, indicating the need to
259 increase vaccine coverage. The significance of targeted vaccination campaigns to safeguard
260 younger age groups with a higher seroprevalence is emphasized by the study's findings. Given the

261 higher seroprevalence in females, there may be gender-specific differences in exposure to the virus
262 that need further investigation.

263 **Conclusions**

264 This study shows a higher prevalence of SARS-CoV-2 antibodies after the second wave of COVID-
265 19 in Tumbes, with a huge prevalence of IgG in individuals younger than 17 years old, more than
266 80% of seropositive patients were asymptomatic in all age groups. The findings suggest that a
267 significant portion of the population was exposed to the virus and developed antibodies,
268 highlighting the importance of continued efforts to control the spread of new variants of the virus
269 through massive campaigns of vaccination.

270

271 **Acknowledgments**

272 We thank the villagers of AAHH Las Flores. LMM and team are grateful to all the regional
273 authorities from the County Town Hall, the Regional Directorate of Health-Tumbes V Jimenez, and
274 J Arias. We are grateful to the members of the Executive Office of Epidemiology N Julca, and L
275 Arevalo. LMM expresses gratitude to the members of the Grupo de Investigación de la Escuela de
276 Medicina. LMM would like to thanks for the aerial photography to JeanPierre. Angie Toledo is
277 doctoral student in the Epidemiological Research Doctorate at Universidad Peruana Cayetano
278 Heredia under FONDECYT/CIENCIACTIVA scholarship EF033-235-2015 and supported by
279 training grant D43 TW007393 awarded by the Fogarty International Center of the US National
280 Institutes of Health. Neither the FONDECYT/CIENCIACTIVA scholarship nor the training grant
281 D43 TW007393 contributed to the development of the present study.

282 **Funding**

283 This project was supported the Regional Directorate of Health from Tumbes, the Regional
284 Government, the local Government of Tumbes and Universidad Nacional de Tumbes.

285

286 **Footnotes**

287 The statements contained in this document are those of the authors and should not be construed as
288 official points of view of the Universidad Cesar Vallejo, Universidad Nacional de Tumbes, or other
289 organizations mentioned.

290

291 **References**

292

- 293 1. Herrera-Añazco P, Uyen-Cateriano A, Mezones-Holguin E, Taype-Rondan A, Mayta-Tristan P,
294 Malaga G, et al. Some lessons that Peru did not learn before the second wave of COVID-19.
295 *Int J Health Plann Manage.* mayo de 2021;36(3):995-8.
- 296 2. Mayta-Tristán P. Los tsunamis por Covid-19 en Perú: El primero malo, segundo peor. *Revista
297 del Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo.* julio de 2021;14(3):260-1.
- 298 3. Gianella C, Gideon J, Romero MJ. What does COVID-19 tell us about the Peruvian health
299 system? *Canadian Journal of Development Studies / Revue canadienne d'études du
300 développement.* 3 de abril de 2021;42(1-2):55-67.
- 301 4. Álvarez-Antonio C, Meza-Sánchez G, Calampa C, Casanova W, Carey C, Alava F, et al.
302 Seroprevalence of anti-SARS-CoV-2 antibodies in Iquitos, Peru in July and August, 2020: a
303 population-based study. *The Lancet Global Health.* 1 de julio de 2021;9(7):e925-31.
- 304 5. Vargas-Herrera N, Araujo-Castillo RV, Mestanza O, Galarza M, Rojas-Serrano N, Solari-Zerpa
305 L. SARS-CoV-2 Lambda and Gamma variants competition in Peru, a country with high
306 seroprevalence. *The Lancet Regional Health – Americas* [Internet]. 1 de febrero de 2022
307 [citado 16 de febrero de 2023];6. Disponible en:
308 [https://www.thelancet.com/journals/lanam/article/PIIS2667-193X\(21\)00108-3/fulltext](https://www.thelancet.com/journals/lanam/article/PIIS2667-193X(21)00108-3/fulltext)
- 309 6. MINSA. Vacuna COVID-19 en el Perú [Internet]. 2023. Disponible en:
310 <https://www.minsa.gob.pe/reunis/data/vacunas-covid19.asp>
- 311 7. MINSA. Covid 19 en el Perú - Ministerio del Salud [Internet]. [citado 4 de julio de 2023].
312 Disponible en: https://covid19.minsa.gob.pe/sala_situacional.asp
- 313 8. CDC PERU. Sala Covid-19, resumen de la situación actual del país. 2023 [citado 16 de junio de
314 2023]. SALA SITUACIONAL COVID 19. Disponible en:
315 [https://public.tableau.com/views/SALASITUACIONALCOVID19/MODELOFINAL?:embed=y&:s
317 howVizHome=no&:host_url=https%3A%2F%2Fpublic.tableau.com%2F&:embed_code_versio
318 n=3&:tabs=no&:toolbar=yes&:animate_transition=yes&:display_static_image=no&:display_s
319 pinner=no&:display_overlay=yes&:display_count=yes&:language=es&publish=yes&:loadOrd](https://public.tableau.com/views/SALASITUACIONALCOVID19/MODELOFINAL?:embed=y&:showVizHome=no&:host_url=https%3A%2F%2Fpublic.tableau.com%2F&:embed_code_version=3&:tabs=no&:toolbar=yes&:animate_transition=yes&:display_static_image=no&:display_s
316 pinner=no&:display_overlay=yes&:display_count=yes&:language=es&publish=yes&:loadOrderID=0)

- 320 9. Gutiérrez-Tudela JW. La pandemia de la COVID-19 en el Perú: análisis epidemiológico de la
321 segunda ola. *Revista de la Sociedad Peruana de Medicina Interna*. 10 de diciembre de
322 2021;34(4):129-129.
- 323 10. Lima EEC, Vilela EA, Peralta A, Rocha M, Queiroz BL, Gonzaga MR, et al. Investigating regional
324 excess mortality during 2020 COVID-19 pandemic in selected Latin American countries.
325 *Genus*. 3 de noviembre de 2021;77(1):30.
- 326 11. CDC. Disponibilidad de camas COVID-19 [Internet]. 2022 [citado 24 de abril de 2023].
327 Disponible en: [https://www.dge.gob.pe/portalnuevo/wp-](https://www.dge.gob.pe/portalnuevo/wp-content/uploads/2022/02/camas_covid_20220222.html)
328 [content/uploads/2022/02/camas_covid_20220222.html](https://www.dge.gob.pe/portalnuevo/wp-content/uploads/2022/02/camas_covid_20220222.html)
- 329 12. Moyano LM, Toledo AK, Chirinos J, Barreto PMQV, Cavalcanti S, Gamboa R, et al. SARS-CoV-2
330 seroprevalence on the north coast of Peru: A cross-sectional study after the first wave. *PLOS*
331 *Neglected Tropical Diseases*. 28 de junio de 2023;17(6):e0010794.
- 332 13. Moyano L, Gamboa R. Prevalencia de COVID-19 asociada con Dengue y Malaria en
333 comunidades rurales y urbanas del norte de Perú. 30 de marzo de 2023 [citado 18 de junio
334 de 2023]; Disponible en: [https://www.protocols.io/view/prevalencia-de-covid-19-asociada-](https://www.protocols.io/view/prevalencia-de-covid-19-asociada-con-dengue-y-mala-cr4gv8tw)
335 [con-dengue-y-mala-cr4gv8tw](https://www.protocols.io/view/prevalencia-de-covid-19-asociada-con-dengue-y-mala-cr4gv8tw)
- 336 14. MINSA. Situación Epidemiología de la COVID-19 [Internet]. 2022. Disponible en:
337 <http://www.dge.gob.pe/portal/docs/tools/teleconferencia/2022/SE132022/03.pdf>
- 338 15. Cisneros S, Nuntón J, Alfaro R. Asociación significativa entre el endoparasitismo intestinal
339 con la edad y la presencia de ectoparásitos en *Canis familiaris* (Linnaeus). *Manglar*. 31 de
340 marzo de 2020;17(1):27-32.
- 341 16. Censos Nacionales 2017 – XII de Población, VII de Vivienda y III de Comunidades Indígenas
342 [Internet]. [citado 22 de junio de 2020]. Disponible en: <http://censo2017.inei.gob.pe/>
- 343 17. Centro Medico Pampa Grande en Tumbes | MINSA [Internet]. ESTABLECIMIENTOS DE SALUD
344 □. [citado 11 de mayo de 2023]. Disponible en:
345 <https://www.establecimientosdesalud.info/tumbes/centro-medico-pampa-grande-tumbes/>
- 346 18. Del Brutto OH, Costa AF, Mera RM, Recalde BY, Bustos JA, García HH. SARS-CoV-2 in Rural
347 Latin America. A Population-based Study in Coastal Ecuador. *Clin Infect Dis*. 15 de julio de
348 2021;73(2):314-7.
- 349 19. INS. FICHA DE REPORTE DE RESULTADOS DE PRUEBA RÁPIDA. COVID-19a [Internet].
350 Disponible en:
351 [https://web.ins.gob.pe/sites/default/files/Archivos/cnsp/coronavirus/prueba_rapida/FICHA](https://web.ins.gob.pe/sites/default/files/Archivos/cnsp/coronavirus/prueba_rapida/FICHA%20DE%20REPORTE%20DE%20RESULTADOS%20DE%20PRUEBA%20R%C3%81PIDAv3.pdf)
352 [%20DE%20REPORTE%20DE%20RESULTADOS%20DE%20PRUEBA%20R%C3%81PIDAv3.pdf](https://web.ins.gob.pe/sites/default/files/Archivos/cnsp/coronavirus/prueba_rapida/FICHA%20DE%20REPORTE%20DE%20RESULTADOS%20DE%20PRUEBA%20R%C3%81PIDAv3.pdf)
- 353 20. Moyano LM, Saito M, Montano SM, Gonzalez G, Olaya S, Ayvar V, et al. Neurocysticercosis
354 as a cause of epilepsy and seizures in two community-based studies in a cysticercosis-
355 endemic region in Peru. *PLoS Negl Trop Dis*. febrero de 2014;8(2):e2692.

- 356 21. Moyano LM, Montano SM, Vilchez Barreto P, Reto N, Larrauri L, Mori N, et al. Prevalence of
357 stroke survival in rural communities living in northern Peru. *PLoS One*. 2021;16(7):e0254440.
- 358 22. Bendavid E, Mulaney B, Sood N, Shah S, Bromley-Dulfano R, Lai C, et al. COVID-19 antibody
359 seroprevalence in Santa Clara County, California. *Int J Epidemiol*. 17 de mayo de
360 2021;50(2):410-9.
- 361 23. Vicentini F, Denadai W, Gomes YM, Rose TL, Ferreira MSR, Le Moullac-Vaidye B, et al.
362 Molecular Characterization of Noroviruses and HBGA from Infected Quilombola Children in
363 Espirito Santo State, Brazil. *PLoS One* [Internet]. 22 de julio de 2013 [citado 24 de octubre de
364 2019];8(7). Disponible en: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3718680/>
- 365 24. Kinoshita R, Jung SM, Kobayashi T, Akhmetzhanov AR, Nishiura H. Epidemiology of
366 coronavirus disease 2019 (COVID-19) in Japan during the first and second waves. *Math Biosci*
367 *Eng*. 13 de abril de 2022;19(6):6088-101.
- 368 25. Mlcochova P, Kemp SA, Dhar MS, Papa G, Meng B, Ferreira IATM, et al. SARS-CoV-2 B.1.617.2
369 Delta variant replication and immune evasion. *Nature*. noviembre de 2021;599(7883):114-9.
- 370 26. Davies NG, Abbott S, Barnard RC, Jarvis CI, Kucharski AJ, Munday JD, et al. Estimated
371 transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. *Science*. 9 de abril de
372 2021;372(6538):eabg3055.
- 373 27. Organización Mundial de la Salud. Orientaciones para la vigilancia de las variantes del SARS-
374 CoV-2: orientaciones provisionales, 9 de agosto de 2021 [Internet]. Organización Mundial de
375 la Salud; 2021 [citado 21 de marzo de 2023]. Report No.: WHO/2019-
376 nCoV/surveillance/variants/2021.1. Disponible en:
377 <https://apps.who.int/iris/handle/10665/345811>
- 378 28. Seguimiento de las variantes del SARS-CoV-2 [Internet]. [citado 21 de marzo de 2023].
379 Disponible en: <https://www.who.int/es/activities/tracking-SARS-CoV-2-variants>
- 380 29. INSTITUTO NACIONAL DE SALUD [Internet]. [citado 21 de marzo de 2023]. Secuenciación
381 Genómica del virus SARS-CoV-2 en el Perú. Disponible en:
382 <https://web.ins.gob.pe/es/covid19/secuenciamiento-sars-cov2>
- 383 30. INSTITUTO NACIONAL DE SALUD [Internet]. [citado 21 de marzo de 2023]. Distribución de
384 casos por las VOC DELTA - ÓMICRON. Disponible en:
385 [https://web.ins.gob.pe/es/covid19/georreferenciacion-casos-variante-preocupacion-](https://web.ins.gob.pe/es/covid19/georreferenciacion-casos-variante-preocupacion-variable-delta)
386 [variable-delta](https://web.ins.gob.pe/es/covid19/georreferenciacion-casos-variante-preocupacion-variable-delta)
- 387 31. Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al. Effectiveness
388 of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. *New England Journal of Medicine*.
389 12 de agosto de 2021;385(7):585-94.
- 390 32. China's inactivated vaccines effective against Delta variant: study [Internet]. [citado 21 de
391 marzo de 2023]. Disponible en: [http://www.news.cn/english/2021-](http://www.news.cn/english/2021-08/23/c_1310144035.htm)
392 [08/23/c_1310144035.htm](http://www.news.cn/english/2021-08/23/c_1310144035.htm)

- 393 33. Reporte Regional Vacuna COVID-19 - Reporte Regional Vacuna COVID-19 - Diresa Tumbes
394 [Internet]. [citado 21 de marzo de 2023]. Disponible en:
395 <https://www.diresatumbes.gob.pe/index.php/covid-19/reporte-regional-vacuna-covid-19>
- 396 34. Frontiers | Impact of the Second Epidemic Wave of SARS-CoV-2: Increased Exposure of
397 Young People [Internet]. [citado 20 de junio de 2023]. Disponible en:
398 <https://www.frontiersin.org/articles/10.3389/fpubh.2021.715192/full>
- 399 35. Munyeku-Bazitama Y, Folefack GT, Yambayamba MK, Tshiminyi PM, Kazenza BM,
400 Otshudiema JO, et al. High SARS-CoV-2 Seroprevalence after Second COVID-19 Wave
401 (October 2020–April 2021), Democratic Republic of the Congo. *Emerg Infect Dis.* enero de
402 2023;29(1):89-97.
- 403 36. Lone KS, Khan SMS, Qurieshi MA, Majid S, Pandit MI, Haq I, et al. Seroprevalence of SARS-
404 CoV-2-specific anti-spike IgM, IgG, and anti-nucleocapsid IgG antibodies during the second
405 wave of the pandemic: A population-based cross-sectional survey across Kashmir, India.
406 *Frontiers in Public Health* [Internet]. 2022 [citado 20 de junio de 2023];10. Disponible en:
407 <https://www.frontiersin.org/articles/10.3389/fpubh.2022.967447>
- 408 37. Sharma N, Sharma P, Basu S, Bakshi R, Gupta E, Agarwal R, et al. Second Wave of the COVID-
409 19 Pandemic in Delhi, India: High Seroprevalence Not a Deterrent? *Cureus* [Internet].
410 octubre de 2021 [citado 20 de junio de 2023];13(10). Disponible en:
411 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8609204/>
- 412 38. Hossain MI, Parvin S, Islam MS, Alam MJ, Podder S, Datta R, et al. Demographic profile and
413 outcome of patients admitted to a COVID dedicated hospital in Bangladesh during the
414 second wave. *Medicine (Baltimore)*. 17 de septiembre de 2021;100(37):e27281.
- 415 39. Romero Ramos CW, Mamani-Urrutia V, Bustamante-López A, Ubillus Arriola G, Tello D. MP,
416 Castillo Díaz ME, et al. Prevalencia y factores de riesgo asociados a infección por virus SARS-
417 CoV-2 en trabajadores del Instituto Nacional de Salud del Niño de Perú, abril 2020 a marzo
418 2021. *Horizonte Médico (Lima)* [Internet]. enero de 2023 [citado 20 de junio de 2023];23(1).
419 Disponible en: [http://www.scielo.org.pe/scielo.php?script=sci_abstract&pid=S1727-
420 558X2023000100003&lng=es&nrm=iso&tlng=es](http://www.scielo.org.pe/scielo.php?script=sci_abstract&pid=S1727-558X2023000100003&lng=es&nrm=iso&tlng=es)
- 421 40. Thakur V, Bhola S, Thakur P, Patel SKS, Kulshrestha S, Ratho RK, et al. Waves and variants of
422 SARS-CoV-2: understanding the causes and effect of the COVID-19 catastrophe. *Infection*. 1
423 de abril de 2022;50(2):309-25.
- 424 41. Kronbichler A, Kresse D, Yoon S, Lee KH, Effenberger M, Shin JI. Asymptomatic patients as a
425 source of COVID-19 infections: A systematic review and meta-analysis. *Int J Infect Dis*.
426 septiembre de 2020;98:180-6.

427

428 **Supporting information**

429

430 S1 Data. Excel spreadsheet containing, in separate sheets, the underlying data used for the
431 statistical analysis and description of variables.

432 S1 Text. Adult informed consent for study participation approved by the institutional review
433 boards of Universidad Peruana Cayetano Heredia.

434 S2 Text. Parent-signed informed consent for minor study participation approved by the
435 institutional review boards of Universidad Peruana Cayetano Heredia.

436 S1 Fig. Enrollment and seroprevalence flowchart of the first and second wave of COVID-19 in two
437 Tumbes settlements. Created with BioRender.com

Enrollment and seroprevalence flowchart of the first and second wave of COVID-19 in two Tumbes settlements

1. Population size



Parita Flores, Tumbes - Peru

Household size: 4.66 individuals in average (range: 2-10) and 10.48 persons in total.

Enrollment period: September 1st and December 31st 2020

2. Demographic characteristics



Age range: 0-100 years

The mean age is 37.14 years. The female population is 50.0% (50/100 years) and the male population is 50.0% (50/100 years).

3. Tests



100% of the population was tested at least once.



100% of the population was tested at least once.

4. Results



100% (100/100) population were enrolled in the first wave.

An average population of 4.66 persons in household.



100% (100/100) population were enrolled in the second wave.

First wave

Second wave



ADRIANOPOLIS, Tumbes - Peru

Household size: 4.66 individuals in average (range: 2-10)

Enrollment period: September 1st and the first day of January 2021



Age range: 0-100 years

The mean age is 36.67 years. The female population is 50.0% (50/100 years) and the male population is 50.0% (50/100 years).



100% of the population was tested at least once.



100% of the population was tested at least once.



100% (100/100) population were enrolled in the first wave.

An average population of 4.66 persons in household.



100% (100/100) population were enrolled in the second wave.